A5024556454- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Cell Adhesion Molecules Research
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Nutrition, Genetics, and Disease
- Cancer therapeutics and mechanisms
- melanin and skin pigmentation
- Atherosclerosis and Cardiovascular Diseases
Duke Medical Center
2024
Duke Cancer Institute
2024
Mayo Clinic
2022-2023
Mayo Clinic in Arizona
2022
University of Puerto Rico System
2019
SCLC is an aggressive malignancy with poor outcome. Most patients have disease recurrence despite treatments multiple modalities. Subtyping of has been proposed recently, and novel agents targeting specific subtypes are actively being investigated. In this study, we evaluated the plasticity in paired pre- post-treatment samples. The aim was to understand possible subtype evolution after chemotherapy resistance that could lead alternate targeted therapy strategies.A total 68 samples from 32...
The Hermansky-Pudlak syndrome (HPS) is an autosomal recessive rare disorder characterized by oculocutaneous albinism, bleeding diathesis, chronic granulomatous colitis and/or pulmonary fibrosis. HPS the most common single-gene in Puerto Rico with a prevalence of 1:1,800 Northwest island. Risk menorrhagia and post-partum hemorrhage (PPH) cases women have been described medical literature, but data regarding comprehensive description diathesis remains lacking. For this reason, we aim to...
This clinical case presents a patient with NSCLC who experienced on-target resistant mutations and tumor cell transformation from adenocarcinoma to large neuroendocrine small carcinoma. Our was successfully treated combination of targeted therapy, immunotherapy chemotherapy based on genetic histologic changes that occurred in period five years.
Abstract Background: Acute lymphoblastic leukemia (ALL) accounts for 80% of leukemias diagnosed in children. In United States (US), ALL 27% cancers children 0 to 19 years old, disproportionally affecting between 2 and 5 years. Even though age patterns are consistent across racial/ethnic groups, the incidence mortality this malignancy is highly variable. For example, Hispanics have a higher lower survival rates when compared non-Hispanic patients, with likelihood recurrence. However, Hispanic...
Background: Acute lymphoblastic leukemia (ALL) accounts for 80% of leukemias diagnosed in children. In United States (US), ALL 27% cancers children 0 to 19 years old, disproportionally affecting between 2 and 5 years. Even though age patterns are consistent across racial/ethnic groups, the incidence mortality this malignancy is highly variable. For example, Hispanics have a higher lower survival rates when compared non-Hispanic patients, with likelihood recurrence. However, Hispanic broad...